<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335315">
  <stage>Registered</stage>
  <submitdate>31/03/2010</submitdate>
  <approvaldate>19/01/2011</approvaldate>
  <actrnumber>ACTRN12611000068965</actrnumber>
  <trial_identification>
    <studytitle>CF-IDEA (Cystic Fibrosis - Insulin Deficiency, Early Action): Randomised controlled trial of once-daily insulin detemir in patients with cystic fibrosis and early insulin deficiency</studytitle>
    <scientifictitle>Randomised controlled trial to determine whether once-daily insulin detemir slows decline in weight and lung function in patients with cystic fibrosis and early insulin deficiency</scientifictitle>
    <utrn />
    <trialacronym>CF-IDEA</trialacronym>
    <secondaryid>ClinicalTrials.gov NCT01100892</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <healthcondition>Insulin Deficiency</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Once-daily insulin detemir (Levemir) administered by subcutaneous injection for 12 months.  Commencing dose 0.1 units/kg/day, titrated in 0.5 unit increments according to the results of home blood glucose monitoring.</interventions>
    <comparator>No insulin (Observation only)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Prevention of decline in weight and lung function assessed by Forced Expiratory Volume in 1 second (FEV1) and Forced Vital Capacity (FVC).</outcome>
      <timepoint>0, 6, 12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Reduced frequency of hospitalisation for acute respiratory illness (assessed from medical records data)</outcome>
      <timepoint>Over 12 months from baseline</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Reduced rate of decline in glycaemic category</outcome>
      <timepoint>Comparing Oral Glucose Tolerance Test (OGTT) at 0 and 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in glycaemic status assessed by glycated haemoglobin (HbA1c) and continuous glucose monitoring (CGM)</outcome>
      <timepoint>HbA1c at 0, 6, 12 months
CGM at 0 and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Improved quality of life, assessed by validated Cystic Fibrosis Quality of Life (CFQOL) questionnaire (Quittner A.L. et al 2000)</outcome>
      <timepoint>0 and 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in additional lung function tests to assess effort-dependent lung function: MIP (Mouth Inspiratory Pressure), MEP (Mouth Expiratory Pressure) and SnIP (Sniff Nasal Inspiratory Pressure)</outcome>
      <timepoint>0, 6, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in maximal isometric Grip-strength of the non-dominant hand, using a handgrip dynamometer</outcome>
      <timepoint>0, 6, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Body composition by DEXA (Dual Energy X-ray Absorptiometry).  Patients at Children's Hospital Westmead (CHW) will also have pQCT (peripheral Quantitative Computed Tomography</outcome>
      <timepoint>0 and 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Bacterial colonisation of sputum</outcome>
      <timepoint>0 and 12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>(1) Patients with Cystic Fibrosis aged &gt;5 yrs attending Sydney Childrens Hospital (SCH), Childrens Hospital Westmead (CHW), John Hunter Childrens Hospital (JHCH), Lady Cilento Children's Hospital Brisbane (LCCB), or Women's and Children's Hospital Adelaide (WCHA).

(2) Cystic Fibrosis Insulin Deficiency Stage 1 or 2 (defined as peak blood glucose &gt;=8.2 and 120-minute blood glucose &lt;11.1mmol/l on OGTT performed within the last 6 months, when respiratory function stable, as judged by the treating respiratory team.</inclusivecriteria>
    <inclusiveminage>5</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>19</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>(1) Diabetes, defined as 120-minute blood glucose on OGTT &gt;=11.1mmol/L or fasting blood glucose &gt;= 7mmol/L. Such patients will be offered insulin treatment as standard clinical care.

(2) Unstable respiratory disease (hospital admission for treatment of respiratory exacerbation within the last month)

(3)  Current treatment with systemic glucocorticoids or treatment with systemic glucocorticoids of more than 1 month duration, within the last 12 months.

(4) Current treatment with fluoroquinolone antibiotics.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>1/12/2010</anticipatedstartdate>
    <actualstartdate>25/01/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Sydney Children's Hospital</primarysponsorname>
    <primarysponsoraddress>High Street
Randwick
NSW 2031</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Australian Cystic Fibrosis Research Trust</fundingname>
      <fundingaddress>P.O. Box 149, North Ryde NSW, 1670</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (NHMRC)</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Children's Hospital at Westmead</othercollaboratorname>
      <othercollaboratoraddress>Locked Bag 4001
Westmead  NSW 2145</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>John Hunter Children's Hospital</othercollaboratorname>
      <othercollaboratoraddress>Locked Bag 1
Hunter Regional Mail Centre
NSW 2310</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Lady Cilento Children's Hospital</othercollaboratorname>
      <othercollaboratoraddress>Raymond Terrace
South Brisbane
QLD 4101</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Women's and Children's Hospital</othercollaboratorname>
      <othercollaboratoraddress>72 King William Road
North Adelaide  
SA 5006</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Cystic Fibrosis (CF) is the most common life-threatening genetic condition affecting Australian children.  As well as repeated lung infections, children with CF develop insulin deficiency and eventually diabetes.  The CF-IDEA trial (Cystic Fibrosis  Insulin Deficiency, Early Action) will determine whether starting insulin treatment before the onset of diabetes (earlier than current practice) will improve the health of children with CF by improving body weight and lung function.</summary>
    <trialwebsite />
    <publication>Hameed S, Morton JR, Jaffe A, Field PI, Belessis Y, Yoong T, Katz T, Verge CF. Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain. Diabetes Care 33, 221-226. 2010

Hameed, S., Morton, J. R., Field, P. I., Belessis, Y., Yoong, T., Katz, T., Woodhead, H. J., Walker, J. L., Neville, K. A., Campbell, T. A., Jaffe, A., Verge, C. F. Once daily insulin detemir in cystic fibrosis. 
Archives of Disease in Childhood 97(5), 464-467. 2012

Hameed, S., Jaffe, A., and Verge, C. F. Cystic Fibrosis Related Diabetes - the end stage of progressive insulin deficiency. Pediatric Pulmonology 46(8), 747-760. 2011.

</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hunter New England Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>7/12/2009</ethicapprovaldate>
      <hrec>Approval Reference No. 09/10/21/5.01 - HREC/09/HNE/339</hrec>
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Charles Verge</name>
      <address>Endocrinology
Sydney Children's Hospital
High Street
Randwick  NSW  2031</address>
      <phone>+61 2 93821456</phone>
      <fax />
      <email>c.verge@UNSW.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Charles Verge</name>
      <address>Endocrinology
Sydney Children's Hospital
High Street
Randwick  NSW  2031</address>
      <phone>+61 2 93821456</phone>
      <fax />
      <email>c.verge@UNSW.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Charles Verge</name>
      <address>Endocrinology
Room P4036, Level 4, Emergency Wing
Sydney Childrens Hospital
High Street, Randwick  NSW  2031
</address>
      <phone>+61293821456</phone>
      <fax />
      <email>c.verge@UNSW.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>